Aside from Reyataz, Bristol is relying heavily on Abilify, the antipsychotic medicine it sells through an agreement with Japan's Otsuka Pharmaceuticals .

FORBES: Unleashing Pharma's Dogs

It recently received approval from the U.S. Food and Drug Administration for a promising schizophrenia drug, Abilify, that was invented by Japan's Otsuka Pharmaceuticals.

FORBES: More Promises From Bristol-Myers

The drug, which was invented by Japan's Otsuka Pharmaceuticals and co-marketed by New York City-based Bristol (nyse: BMY - news - people ), has much less severe side effects than current anti-psychotic treatments.

FORBES: Magazine Article